

**(E)-4-[4-[2-(2,4-Dinitrophenoxy)ethoxy]-3-methoxybenzylideneamino]-1,5-dimethyl-2-phenyl-1H-pyrazol-3(2H)-one****Chun-Hua Diao\* and Zuo-Liang Jing**


College of Sciences, Tianjin University of Science and Technology, Tianjin 300222, People's Republic of China

Correspondence e-mail:  
diao\_chunhua@163.com**Key indicators**Single-crystal X-ray study  
 $T = 294$  K  
Mean  $\sigma(\text{C}-\text{C}) = 0.004$  Å  
 $R$  factor = 0.048  
 $wR$  factor = 0.131  
Data-to-parameter ratio = 14.5For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.

In the title compound,  $\text{C}_{27}\text{H}_{25}\text{N}_5\text{O}_8$ , the *p*-vanillin (4-hydroxy-3-methoxybenzaldehyde) group makes dihedral angles of 5.80 (8), 66.34 (6) and 68.13 (7)° with the pyrazolone ring, the terminal dinitrobenzene ring and the terminal phenyl ring, respectively. The crystal packing is stabilized by intermolecular  $\text{C}-\text{H}\cdots\text{O}=\text{C}$  and  $\text{C}-\text{H}\cdots\text{O}=\text{N}$  hydrogen bonds that form centrosymmetric dimers.

Received 8 September 2006  
Accepted 17 September 2006**Comment**

There has been a steady growth of interest in the structure and reactivity of Schiff bases owing to their potential biological activities such as antibacterial and antitumor (Klayman *et al.*, 1979). Consequently, a significant effort has been devoted to the synthesis of Schiff base derivatives (Santos *et al.*, 2001). Among the large number of such compounds, 4-amino-1,5-dimethyl-2-phenylpyrazol-3-one forms a variety of Schiff bases with aldehydes, and the synthesis and crystal structures of some of them, such as 4-[(2-hydroxy-3-methoxybenzylidene)amino]-1,5-dimethyl-2-phenyl-1H-pyrazol-3(2H)-one (Diao *et al.*, 2005), (*E*)-4-[3-(4-chlorobenzoyloxy)-4-methoxybenzylideneamino]-1,5-dimethyl-2-phenyl-1H-pyrazol-3(2H)-one (Duan *et al.*, 2006) and (*E*)-4-[2-[2-(2,4-dinitrophenoxy)ethoxy]-3-methoxybenzylideneamino]-1,5-dimethyl-2-phenyl-1H-pyrazol-3(2H)-one (Diao & Yu, 2006), have been reported. We report here the synthesis and structure of the title compound, (I) (Fig. 1).



The bond lengths and angles in (I) are within normal ranges (Allen *et al.*, 1987). The pyrazolone ring (C17/C18/C20/N3/N4/N5/O8) is almost planar, with an r.m.s. deviation for fitted atoms of 0.0467 Å. It makes a dihedral angle of 65.70 (7)° with the attached phenyl ring (C22–C27). The *p*-vanillin unit (C9–C14/C16/O6/O7) is planar, with an r.m.s. deviation for fitted atoms of 0.0175 Å, and makes dihedral angles of 5.80 (8), 66.34 (6) and 68.13 (7)° with the pyrazolone ring, the terminal C1–C6 benzene ring and the terminal phenyl ring, respectively. The crystal packing is stabilized by weak non-classical intermolecular  $\text{C1}-\text{H1}\cdots\text{O8}^i=\text{C20}^i$  and  $\text{C21}-\text{H21B}\cdots\text{O4}^{ii}=\text{N2}^{ii}$  hydrogen bonds (symmetry codes as given in Table 1), each of which forms a centrosymmetric dimer (Fig. 2).

Experimental

An anhydrous ethanol solution (30 ml) of 4-[2-(2,4-dinitrophenoxy)ethoxy]-3-methoxybenzaldehyde (3.62 g, 10 mmol) was added to an anhydrous ethanol solution (30 ml) of 4-amino-1,5-dimethyl-2-phenylpyrazol-3-one (2.03 g, 10 mmol) and the mixture was stirred at 350 K for 5 h under nitrogen, giving a yellow precipitate. The product was isolated and recrystallized from acetonitrile, and then dried in a vacuum to give the pure compound (I) in 85% yield. Yellow single crystals suitable for X-ray analysis were obtained by slow evaporation of an acetonitrile solution.

Crystal data

$C_{27}H_{25}N_5O_8$   $V = 1293.0 (9) \text{ \AA}^3$   
 $M_r = 547.52$   $Z = 2$   
 Triclinic,  $P\bar{1}$   $D_x = 1.406 \text{ Mg m}^{-3}$   
 $a = 9.032 (4) \text{ \AA}$  Mo  $K\alpha$  radiation  $\mu = 0.11 \text{ mm}^{-1}$   
 $b = 12.288 (5) \text{ \AA}$   $T = 294 (2) \text{ K}$   
 $c = 13.054 (5) \text{ \AA}$  Block, yellow  
 $\alpha = 63.883 (7)^\circ$   $0.26 \times 0.20 \times 0.14 \text{ mm}$   
 $\beta = 83.801 (7)^\circ$   
 $\gamma = 88.328 (7)^\circ$

Data collection

Bruker SMART APEX CCD area-detector diffractometer 7445 measured reflections  
 5269 independent reflections  
 $\varphi$  and  $\omega$  scans 2900 reflections with  $I > 2\sigma(I)$   
 Absorption correction: multi-scan (*SADABS*; Sheldrick, 1996)  $R_{int} = 0.025$   
 $T_{min} = 0.959$ ,  $T_{max} = 0.985$   $\theta_{max} = 26.6^\circ$

Refinement

Refinement on  $F^2$  H-atom parameters constrained  
 $R[F^2 > 2\sigma(F^2)] = 0.048$   $w = 1/[\sigma^2(F_o^2) + (0.0611P)^2]$   
 $wR(F^2) = 0.131$  where  $P = (F_o^2 + 2F_c^2)/3$   
 $S = 0.99$   $(\Delta/\sigma)_{max} = 0.004$   
 5269 reflections  $\Delta\rho_{max} = 0.21 \text{ e \AA}^{-3}$   
 364 parameters  $\Delta\rho_{min} = -0.20 \text{ e \AA}^{-3}$

Table 1

Hydrogen-bond geometry ( $\text{\AA}$ ,  $^\circ$ ).

$D-H\cdots A$	$D-H$	$H\cdots A$	$D\cdots A$	$D-H\cdots A$
$C1-H1\cdots O8^i$	0.93	2.50	3.258 (3)	139
$C21-H21B\cdots O4^{ii}$	0.96	2.56	3.131 (3)	119

Symmetry codes: (i)  $-x + 2, -y + 1, -z$ ; (ii)  $-x + 2, -y + 2, -z$ .

H atoms were included in calculated positions ( $C-H = 0.93-0.97 \text{ \AA}$ ) and refined as riding, with  $U_{iso}(H) = 1.2U_{eq}(C)$  or  $1.5U_{eq}(\text{methyl C})$ .

Data collection: *SMART* (Bruker, 1999); cell refinement: *SAINT* (Bruker, 1999); data reduction: *SAINT*; program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997a); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997a); molecular graphics: *SHELXTL* (Sheldrick, 1997b); software used to prepare material for publication: *SHELXTL*.




Figure 1 The molecular structure of (I), with displacement ellipsoids for non-H atoms drawn at the 30% probability level.




Figure 2 Partial packing diagram of (I), showing intermolecular  $C-H\cdots O$  hydrogen bonds (dashed lines).

References

Allen, F. H., Kennard, O., Watson, D. G., Brammer, L., Orpen, A. G. & Taylor, R. (1987). *J. Chem. Soc. Perkin Trans. 2*, pp. S1–19.  
 Bruker (1999). *SMART* (Version 5.0) and *SAINT* (Version 4.0). Bruker AXS Inc., Madison, Wisconsin, USA.  
 Diao, C.-H., Fan, Z., Yu, M., Chen, X., Jing, Z.-L. & Deng, Q.-L. (2005). *Acta Cryst. E61*, o3271–o3272.  
 Diao, C.-H. & Yu, M. (2006). *Acta Cryst. E62*, o4482–o4483.  
 Duan, Z.-Y., Zhang, W.-J., Li, G., Han, E.-S. & Du, F.-Y. (2006). *Acta Cryst. E62*, o2997–o2998.  
 Klayman, D. L., Bartosevich, J. F., Griffin, T. S., Mason, C. J. & Scovill, J. P. (1979). *J. Med. Chem.* **22**, 855–862.  
 Santos, M. L. P., Bagatin, I. A., Pereira, E. M. & Ferreira, A. M. D. C. (2001). *J. Chem. Soc. Dalton Trans.* pp. 838–844.  
 Sheldrick, G. M. (1996). *SADABS*. University of Göttingen, Germany.  
 Sheldrick, G. M. (1997a). *SHELXS97* and *SHELXL97*. University of Göttingen, Germany.  
 Sheldrick, G. M. (1997b). *SHELXTL*. Version 5.10. Bruker AXS Inc., Madison, Wisconsin, USA.